Upstate Active Clinical Trials
Study Title:
AALL1731 - A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)What is the purpose of the study? (in Layman's terms, please describe the study)
A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)Upstate Institutional Review Board (IRB) Number:
1464114Study/Protocol ID:
AALL1731Study Phase:
IIIPatient Age Group:
ChildrenPrincipal Investigator:
Melanie A ComitoWho is eligible?
Patients must be > 365 days and < 10 years of age (B-ALL patients without DS)Patients must be > 365 days and ≤ 31 years of age (B-ALL patients with DS)
Patients must be > 365 days and ≤ 31 years of age (B-LLy patients with or without DS)
What is involved if I participate?
- How long is the study?
Treatment is 2 years from the start of Interim Maintenance I and then followed on study for 10 years. - Is transportation provided or reimbursed?
No - Is parking provided or reimbursed?
Yes - What tests and procedures are involved?
lab draws, bone marrow aspirate/biopsy, lumbar puncture
Where will the study take place?
Pediatric Cancer CenterOther Information:
N/AWho can I contact for more information?
Name: Karen B Bilynsky
Phone: 315-464-7601
Email: [email protected]